Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011570 (
depression
)
172,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The decapeptide
Cetrorelix
, an LHRH antagonist, inhibits gonadotropin and sex steroid secretion.
Cetrorelix
is used for IVF-ET procedures and for the treatment of patients with prostate carcinoma, benign prostatic hyperplasia, endometriosis, leiomyomas and, ovarian cancer. However little is known about the effects of
Cetrorelix
on the brain function. In the present work the influence of
Cetrorelix
on different aspects of the brain function was studied following its administration into the lateral brain ventricle in mice. The effects tested included the impairment of the consolidation of a passive avoidance reflex caused by beta-amyloid 25-35, anxiolytic action in the plus-maze, antidepressive action in a forced swimming test and a tail suspension test and open-field behavior. In the passive avoidance test, beta-amyloid 25-35 administered immediately after the learning trial impaired the consolidation of passive avoidance learning.
Cetrorelix
fully blocked the impairment of the consolidation of passive avoidance learning when given icv 30 min following beta-amyloid 25-35 administration. If beta-amyloid 25-35 and
Cetrorelix
icv were given simultaneously, the
Cetrorelix
attenuated, but did not block the action of the beta-amyloid 25-35.
Cetrorelix
elicited anxiolytic action in the plus-maze, depending on the dose used. In the forced swimming and tail suspension tests,
Cetrorelix
demonstrated antidepressive-like action. Concerning open-field behavior,
Cetrorelix
displayed no action on locomotion, rearing or grooming. The results demonstrate that
Cetrorelix
affects brain function: and is able to correct the impairment of the memory consolidation caused by beta-amyloid 25-35.
Cetrorelix
also elicits anxiolytic and antidepressive action, but it does not influence the open-field activity. Further experimental work with
Cetrorelix
is necessary, but the results imply the possible merit of a clinical trial with
Cetrorelix
in patients with anxiety,
depression
and Alzheimer's disease.
...
PMID:Effects of the LHRH antagonist Cetrorelix on the brain function in mice. 1937 62
The decapeptide LHRH antagonist,
Cetrorelix
, inhibits gonadotropin and sex-steroid secretion.
Cetrorelix
is used for IVF-ET procedures and for the treatment of benign prostatic hyperplasia, endometriosis and leiomyomas. However little is known about the effects of
Cetrorelix
on brain functions. Previously we have tested
Cetrorelix
in mice on the impairment of the consolidation of a passive avoidance behavior caused by beta-amyloid 25-35, anxiolytic action in the plus-maze, antidepressive action in a forced swimming test, tail suspension and open-field behavior following its administration into the lateral brain ventricle. In the present study we repeated and extended the experiments in rats in order to determine whether there are species differences in the action of
Cetrorelix
between mice and rats. The effects of
Cetrorelix
evaluated included the methods used in mice without tail suspension test and extended by measuring core temperature.
Cetrorelix
fully blocked the impairment of the consolidation of passive avoidance learning when given icv 30 min following administration of beta-amyloid 25-35. If beta-amyloid 25-35 and
Cetrorelix
were given simultaneously,
Cetrorelix
was ineffective.
Cetrorelix
elicited slight anxiogenic and stronger anxiolytic action in the plus-maze, depending on the dose used. In the forced swimming tests,
Cetrorelix
showed antidepressive-like action. In open-field behavior tests
Cetrorelix
displayed a U-type action on locomotion with 0.5 and 2 microg increasing locomotion, and increase rearing but and had no effect on grooming at 0.5-2 microg.
Cetrorelix
had no action on core temperature. Our findings demonstrate that
Cetrorelix
is able to correct the impairment of the memory consolidation caused by beta-amyloid 25-35.
Cetrorelix
elicits anxiolytic and antidepressive action, slightly increases locomotion and rearing in open field, but it does not influence the core temperature. The results obtained in rats are similar to those reported previously by us in mice. Collectively our findings confirm the effects of
Cetrorelix
on brain function in two species and suggest the possible merit of a clinical trial with
Cetrorelix
in patients with anxiety,
depression
and Alzheimer's disease.
...
PMID:Effects of the LHRH antagonist Cetrorelix on affective and cognitive functions in rats. 1970 9